Group 1 - The core viewpoint of the article highlights that Guangdong Wannianqing Pharmaceutical Co., Ltd. is experiencing temporary performance pressure due to strategic investments in new business areas as part of its "one core, multiple wings" health ecosystem initiative [1][2] - In 2024, the company reported a revenue of 279 million yuan, a year-on-year decline of 4.71%, and a net profit attributable to shareholders of 4.16 million yuan, a decrease of 29.34 million yuan compared to the previous year [1] - The company incurred a loss of 6.53 million yuan in its net profit after deducting non-recurring items, primarily due to increased costs from new business investments, including healthcare services and upstream acquisitions [1] Group 2 - In the first quarter of 2025, the company achieved a revenue of 70.81 million yuan, a slight year-on-year decrease of 0.54%, with a net loss attributable to shareholders of 3.44 million yuan [1] - The decline in profits during the first quarter is attributed to ongoing market cultivation for new business segments, increased personnel and amortization costs, and promotional expenses related to the acquisition of Hainan Wanmitang Pharmaceutical Co., Ltd. [1][2] - The company is focusing on the health industry, emphasizing innovation in its pharmaceutical core business and digital retail platforms, while developing three new business segments: traditional Chinese medicine, healthcare services, and health food [2]